Fortitude Family Office’s Quince Therapeutics QNCX Stock Holding History

Fortitude Family Office’s Portfolio QNCX Stock Details QNCX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-40	Closed	-$821	–	2362
2026 Q1	$821	Buy	+40	New	+$8.03K	﹤0.01%	1559

Other funds holding QNCX

WIM

Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return

Fortitude Family Office's QNCX Position: Q2 2026 in Review

Fortitude Family Office sold out of Quince Therapeutics (QNCX) in Q2 2026, closing a stake of 40 shares — an estimated $821 sold.

Fortitude Family Office first reported a position in QNCX in Q1 2026 and held it in 1 quarter. The position peaked at $821 in Q1 2026. 1 fund tracked by Wall St. Rank holds QNCX as of Q2 2026.

Fortitude Family Office reported no remaining Quince Therapeutics position as of Q2 2026 after selling out during the quarter.
Fortitude Family Office sold 40 Quince Therapeutics shares in Q2 2026, an estimated $821.
Fortitude Family Office first reported a position in Quince Therapeutics in Q1 2026 and held it in 1 quarter.
Fortitude Family Office's Quince Therapeutics position peaked at $821 in Q1 2026.
1 fund tracked by Wall St. Rank held Quince Therapeutics as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.